Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30277338 | 1.00 | HTR2A (0.55) | HTR2AHTR2CADRA1ATAAR1POLB | |
| SCHEMBL24733403 | 0.92 | HTR2A (0.60) | HTR2AHTR2CADRA1ATAAR1MEN1 | |
| SCHEMBL31614533 | 0.86 | HTR2A (0.53) | HTR2AHTR2CPOLBKMT2A | |
| SCHEMBL24734861 | 0.86 | HTR2A (0.46) | HTR2AHTR2C | |
| SCHEMBL24733377 | 0.85 | HTR2A (0.55) | HTR2AHTR2CADRA1ATAAR1 | |
| SCHEMBL31188806 | 0.85 | HTR2A (0.61) | HTR2AHTR2CADRA1ATAAR1 | |
| SCHEMBL24733560 | 0.85 | HTR2A (0.55) | HTR2AHTR2CADRA1ATAAR1 | |
| SCHEMBL24733557 | 0.85 | HTR2A (0.61) | HTR2AHTR2CADRA1ATAAR1 | |
| Hydrochloric Acid SCHEMBL26097571 | 0.84 | HTR2A (0.54) | HTR2AHTR2CADRA1ATAAR1 | |
| SCHEMBL24734851 | 0.84 | HTR2A (0.54) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637736-A1 | PRODRUGS OF DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250282712-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI THERAPEUTICS INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12351537-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | ATAI THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240294461-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2024-09-05 | — | — | US | disclosed |
| WO-2024138041-A1 | PRODRUGS OF DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ENTHEOGENIX BIOSCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138041-A1 | PRODRUGS OF DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ENTHEOGENIX BIOSCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-11926574-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | Atai Therapeutics Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117500487-A | Dimethoxy phenyl alkylamine activators of serotonin receptors | 恩泰奥吉尼克斯生物科学公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2022261240-A2 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11926574-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | HTR1A, HTR7, HTR4 | HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885 |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885 |
| US-12351537-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | HTR1A, HTR7, HTR4 | HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885 |
| US-20250282712-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885 |
| US-20240294461-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | HTR2A 12/4885HTR2C 8/4885ADRA1A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.